Daptomycin Effective in Treating Serious Skin Infections in Children

Daptomycin, part of a new class of antibiotics currently approved only for use in adults, is effective and well-tolerated in children. <i>Photo Credit: CDC/Janice Haney Carr/Jeff Hageman, MHS.</i>
Daptomycin, part of a new class of antibiotics currently approved only for use in adults, is effective and well-tolerated in children. Photo Credit: CDC/Janice Haney Carr/Jeff Hageman, MHS.

Findings from a first-of-its-kind clinical trial suggest that intravenous daptomycin may be effective and well-tolerated in children, possibly providing an alternative treatment against methicillin-resistant Staphylococcus aureus (MRSA) skin infections in this patient population. The findings were published in Pediatrics.1

Daptomycin is active against MRSA and is currently only approved for adult use in treating skin and skin structure infections, and bloodstream infections.

“The safety and efficacy of intravenous daptomycin was comparable to standard-of-care IV antibiotics used for hospitalized children, usually vancomycin or clindamycin for MRSA and cefazolin for methicillin-susceptible strains of S aureus,” said lead author, John Bradley, MD, professor of clinical pediatrics, co-chief of the Division of Infectious Diseases at UC San Diego School of Medicine in California, in a news release.2

The study was randomized and investigator-blinded, and included 257 children aged 1 to 17 years who were exposed to daptomycin, and 132 children treated with standard of care (SOC; primarily clindamycin or vancomycin). All patients had complicated skin and skin structure infections (cSSSI), with 35% having confirmed methicillin-resistant Staphylococcus aureus

Results showed that daptomycin had similar safety to the SOC, with the proportions of safety population patients with treatment-related adverse events similar between the daptomycin (14%) and SOC (17%) group. Incidence of diarrhea was 7% and 5% for daptomycin and SOC; and increases in creatine phosphokinase were 6% and 5%, respectively.

Clinical success rate — defined by blinded evaluator-assessed complete/partial resolution of cSSSI symptoms 7–14 days after treatment — in the intent-to-treat population were also similar for the daptomycin (91%) and SOC group.

Dosing strategies were initially based on adult experiences but were then changed when the researchers found that the younger the child, the more quickly their bodies eliminated daptomycin.

The Food and Drug Administration is currently reviewing whether to approve daptomycin use in children.

References

  1. Bradley J, Glasser C, Patino H, et al. Daptomycin for complicated skin infections: a randomized trial [published online February 15, 2017]. Pediatrics. doi: 10.1542/peds.2016-2477
  2. Scott LaFee; Antibiotic effective against drug-resistant bacteria in pediatric skin infections [news release]. San Diego, CA: UC San Diego Health. Published February 16, 2017. Accessed February 20, 2017.
You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters